MYOF Antibodies

Structure of MYOF

The molecular weight of the protein encoded by the MYOF gene is approximately 65 kDa, and this value fluctuates slightly among different mammalian species due to differences in amino acid sequences. Take the human MYOF protein as an example. It contains approximately 1,870 amino acids and forms specific spatial conformations through its FERM, Myosin and other domains, mediating the interaction between the cytoskeleton and the cell membrane. The key domains in its tertiary structure can recognize and bind to substrates such as actin, thereby regulating the processes of vesicle transport and membrane remodeling. Although this protein does not contain a cofactor, the synergistic effect of its multiple functional domains is crucial for its physiological functions such as muscle fiber repair and membrane protein localization.

Fig. 1 Altered 3D conformation and steric hindrance in a MYOF variant.¹

Key structural properties of MYOF:

• Contains several modular domains such as FERM and Myosin
• Interact with the phospholipids of the cell membrane through the FERM domain
• Rely on the Myosin domain to bind to the actin cytoskeleton

Functions of MYOF

The core function of the MYOF gene-encoded protein is to mediate the dynamic connection between the cell membrane and the cytoskeleton and regulate intracellular vesicle transport. Its specific functions in muscle tissue include:

This protein senses changes in membrane lipid components through its FERM domain and then recruits downstream signaling molecules to form a precise regulatory network for the stability of muscle cell membranes.

Applications of MYOF and MYOF Antibody in Literature

• Gao, Dehua, et al. "Chronic systemic capillary leak syndrome with lymphatic capillaries involvement and MYOF mutation: case report and literature review." Frontiers in Genetics 14 (2023): 1282711.https://doi.org/10.3389/fgene.2023.1282711 

This study reports a 58-year-old patient with chronic SCLS who improved after treatment and was found to have a p.K1865R variant in the MYOF gene through sequencing. This variant may increase vascular permeability by affecting the VEGF signaling pathway, revealing a new potential pathogenic mechanism of SCLS.

• Zhou, Yang, et al. "Myoferlin alleviates pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting NLRP3-mediated pyroptosis." PeerJ 12 (2024): e18499. https://doi.org/10.7717/peerj.18499

Studies have shown that the musculosecreted protein MYOF can improve cardiac hypertrophy and function. The mechanism is related to the inhibition of NLRP3 inflammasome-mediated pyroptosis of cardiomyocytes, providing a new potential target for the treatment of cardiac hypertrophy.

• Kiselev, Artem, et al. "Truncating variant in myof gene is associated with limb-girdle type muscular dystrophy and cardiomyopathy." Frontiers in genetics 10 (2019): 608. https://doi.org/10.3389/fgene.2019.00608 

This study has for the first time discovered that MYOF gene mutations can lead to human cardiomyopathy and limb-band muscular dystrophy. Through the verification of patient cells and zebrafish models, a new pathogenic role of Myofin, a member of the myoglobin family, in muscle diseases was revealed.

• Wei, Chi-Hsuan, et al. "E3 ligase TRIM8 suppresses lung cancer metastasis by targeting MYOF degradation through K48-linked polyubiquitination." Cell Death & Disease 16.1 (2025): 88. https://doi.org/10.1038/s41419-025-07421-6

This study reveals that the E3 ubiquitin ligase TRIM8 plays a tumor suppressor role in non-small cell lung cancer. It inhibits tumor metastasis by mediating the ubiquitination and degradation of MYOF, providing new biomarkers and targets for the treatment of lung cancer.

• Zhang, Tao, et al. "A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer." Nature Communications 9.1 (2018): 3726. https://doi.org/10.1038/s41467-018-06179-0 

This study screened out a novel small molecule, WJ460, which can effectively inhibit the invasion and metastasis of breast cancer cells. Experiments have confirmed that its targeted protein MYOF is a key factor in cancer metastasis, and targeted inhibition of MYOF provides a new strategy for the treatment of related cancers.

Creative Biolabs: MYOF Antibodies for Research

Creative Biolabs specializes in the production of high-quality MYOF antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom MYOF Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our MYOF antibodies, custom preparations, or technical support, contact us at email.